DK3420084T3 - Hidtil ukendt tilgang til behandling af inflammatoriske forstyrrelser - Google Patents
Hidtil ukendt tilgang til behandling af inflammatoriske forstyrrelser Download PDFInfo
- Publication number
- DK3420084T3 DK3420084T3 DK17706515.8T DK17706515T DK3420084T3 DK 3420084 T3 DK3420084 T3 DK 3420084T3 DK 17706515 T DK17706515 T DK 17706515T DK 3420084 T3 DK3420084 T3 DK 3420084T3
- Authority
- DK
- Denmark
- Prior art keywords
- unpermanent
- approach
- treatment
- inflammatory disorders
- disorders
- Prior art date
Links
- 0 B*(C1OC)O[C@@](C*)C1O*(OC)=O Chemical compound B*(C1OC)O[C@@](C*)C1O*(OC)=O 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/127—DNAzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16000468.5A EP3211081A1 (en) | 2016-02-26 | 2016-02-26 | Novel approach for treating inflammatory disorders |
| EP16002305 | 2016-10-27 | ||
| PCT/EP2017/054374 WO2017144685A1 (en) | 2016-02-26 | 2017-02-24 | Novel approach for treating inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3420084T3 true DK3420084T3 (da) | 2021-10-25 |
Family
ID=58098650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17706515.8T DK3420084T3 (da) | 2016-02-26 | 2017-02-24 | Hidtil ukendt tilgang til behandling af inflammatoriske forstyrrelser |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10647987B2 (da) |
| EP (1) | EP3420084B1 (da) |
| JP (1) | JP7065778B2 (da) |
| DK (1) | DK3420084T3 (da) |
| ES (1) | ES2895275T3 (da) |
| WO (1) | WO2017144685A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111440723A (zh) * | 2020-03-04 | 2020-07-24 | 西北农林科技大学 | 刺激Th17细胞增殖活化的肠道微生物培养基及培养方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309406A (en) | 1979-07-10 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4309404A (en) | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US4556552A (en) | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
| US4704295A (en) | 1983-09-19 | 1987-11-03 | Colorcon, Inc. | Enteric film-coating compositions |
| WO2004024880A2 (en) | 2002-09-16 | 2004-03-25 | Exelixis, Inc. | AMPDs AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
| DE10346487A1 (de) | 2003-10-02 | 2005-05-12 | Transmit Technologietransfer | Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels |
| JP2008505080A (ja) | 2004-07-01 | 2008-02-21 | ニューヨーク ユニバーシティー | ＲＯＲγｔ機能の調節のための組成物および方法 |
| US7897583B2 (en) * | 2005-05-24 | 2011-03-01 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to PTPRU |
| WO2008113832A2 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA |
| WO2011113015A2 (en) | 2010-03-12 | 2011-09-15 | Avi Biopharma, Inc. | Antisense modulation of nuclear hormone receptors |
| US9629910B2 (en) * | 2011-03-22 | 2017-04-25 | The Brigham And Women's Hospital, Inc. | Use of Th9 cells and IL-9 for the treatment of melanoma |
| CN102732562A (zh) | 2012-06-27 | 2012-10-17 | 中国人民解放军第三军医大学 | 抑制cyp2c8基因表达的方法 |
| EA201591595A1 (ru) | 2013-03-27 | 2016-05-31 | Исарна Терапьютикс Гмбх | Модифицированные олигонуклеотиды трф-бета2 |
-
2017
- 2017-02-24 EP EP17706515.8A patent/EP3420084B1/en active Active
- 2017-02-24 ES ES17706515T patent/ES2895275T3/es active Active
- 2017-02-24 JP JP2018544810A patent/JP7065778B2/ja active Active
- 2017-02-24 WO PCT/EP2017/054374 patent/WO2017144685A1/en active Application Filing
- 2017-02-24 US US16/079,588 patent/US10647987B2/en active Active
- 2017-02-24 DK DK17706515.8T patent/DK3420084T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3420084B1 (en) | 2021-08-04 |
| US10647987B2 (en) | 2020-05-12 |
| WO2017144685A1 (en) | 2017-08-31 |
| JP7065778B2 (ja) | 2022-05-12 |
| US20190055566A1 (en) | 2019-02-21 |
| JP2019506174A (ja) | 2019-03-07 |
| ES2895275T3 (es) | 2022-02-18 |
| EP3420084A1 (en) | 2019-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3364993T3 (da) | Fremgangsmåder til behandling af angelman syndrom | |
| DK3212226T3 (da) | Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser | |
| DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3777855T3 (da) | Fremgangsmåder til behandling af fibrotiske sygdomme | |
| DK3269716T3 (da) | Hidtil ukendte forbindelser og farmaceutiske sammensætninger deraf til behandling af inflammatoriske lidelser | |
| DK3224269T3 (da) | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser | |
| DK3261721T3 (da) | Anvendelse af pridopidin til forbedring af hukommelse | |
| DK3265085T3 (da) | Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser | |
| DK3102213T3 (da) | Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3169328T3 (da) | Quinolinderivater til behandling af inflammationssygdomme | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3626270T3 (da) | Behandling af kardiovaskulære sygdomme | |
| DK3261726T3 (da) | Sammensætning til behandling af acne | |
| DK3498278T3 (da) | Forbindelser til behandling af sygdomme relateret til DUX4-ekspression | |
| DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
| DK3283210T3 (da) | Fremgangsmåde | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| DK3164394T3 (da) | Gls1-inhibitorer til behandling af sygdomme | |
| DK2961378T3 (da) | Fremgangsmåder til behandlingen af mitochondrisk sygdom | |
| DK3548061T3 (da) | Behandling af neurologiske sygdomme | |
| DK3192524T3 (da) | Hgf præparat egnet til behandling af neurologiske lidelser |